



Universiteit
Leiden

The Netherlands

Evaluation of molecular profiling platforms in clinical pharmacology

Doorn, M.B.A. van

Citation

Doorn, M. B. A. van. (2007, May 24). *Evaluation of molecular profiling platforms in clinical pharmacology*. Retrieved from <https://hdl.handle.net/1887/11974>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/11974>

Note: To cite this publication please use the final published version (if applicable).

VOOR MIJN OUDERS

EVALUATION
OF MOLECULAR
PROFILING
PLATFORMS
IN CLINICAL
PHARMACOLOGY

Proefschrift

ter verkrijging van de graad van Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus prof. mr. P. F. van der Heijden,
volgens besluit van het College voor Promoties te verdedigen op
donderdag 24 mei 2007 te klokke 16.15

door

Martijn Bastiaan Adriaan van Doorn
Geboren te Tilburg in 1974

PROMOTIECOMMISSIE

PROMOTOR

Prof. Dr. A.F. Cohen

CO-PROMOTERES

Dr. J. Burggraaf

Dr. E.J. van Hoogdalem

REFERENT

Prof. Dr. G.J. van Ommen

OVERIGE LEDEN

Prof. Dr. J. van der Greef

Prof. Dr. J.A. Romijn

Prof. Dr. H.J. Guchelaar

DESIGN

Caroline de Lint, Voorburg (caro@delint.nl)

The investigations described in this thesis were supported by corporate funding from Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium and performed at the Centre for Human Drug Research, Leiden University Medical Centre, The Netherlands.

The printing of this thesis was financially supported by the foundation Centre for Human Drug Research, Leiden, The Netherlands.

Section 1	General Introduction
1	Introduction and outline of the thesis – 10
2	Introduction to molecular profiling platforms – 22
Section 2	Evaluation of ‘traditional’ versus ‘non-traditional’ biochemical markers in clinical pharmacology
3	Evaluation of pro-inflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in type 2 Diabetes Mellitus patients and healthy volunteers – 46
4	Evaluation of monocyte chemoattractant protein 1 and tumour necrosis factor alpha as biomarkers for rapid pharmacological effects of fibrates in type 2 Diabetes Mellitus patients and healthy volunteers – 64
Section 3	Evaluation of cDNA microarray-based transcriptomics in clinical pharmacology
5	Evaluation of skeletal muscle and adipose tissue biopsy procedures for microarray-based gene expression profiling – 86
6	Evaluation of gene expression profiles as biomarkers for the pharmacological effects of thiazolidinediones in type 2 Diabetes Mellitus patients and healthy volunteers – 100
7	Evaluation of gene expression profiles as biomarkers for the pharmacological effects of fibrates in type 2 Diabetes Mellitus patients and healthy volunteers – 118
Section 4	Evaluation of ¹H NMR spectroscopy-based metabolomics in clinical pharmacology
8	Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in type 2 Diabetes Mellitus patients and healthy volunteers – 140
9	NMR-based metabolomics of urine from an exploratory study of ciprofibrate in healthy volunteers and patients with type 2 Diabetes Mellitus – 156
Section 5	Summary and conclusions
10	Summary and conclusions – 174
11	General discussion – 182
12	Nederlandse inleiding, samenvatting en conclusies – 192
	Illustrations / Illustraties – 201
	Curriculum Vitæ – 231